P/B
2,4
Coya Therapeutics
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
$101.8M
Market Cap • 10/15/2026
2020
(6 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
12,7
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,8
EPS
—
Market Cap
Market Cap
101,8M
EV
58,6M
EV/Revenue
7,3
EV/EBITDA
-2,5
EV/EBIT
-2,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-30,8%
Total Yield
-30,8%
Payout
0%
Retained Earnings
-75,8M
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
211,8%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
1,9
Debt/Equity
0%
Current Ratio
13,4
Quick Ratio
12,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!